Anaemia and pathologic complete response rate according to carboplatin dose in HER2+ breast cancer treated with neoadjuvant TCHP.

Cancer Med · 2023 · PMC9883435 · PMID 35837812

Europe PMC DOI

hedged sentence

0.0530

closest p · 1.1× alpha

0.0530

boldest claim

The sentences

marginally significantp = 0.053so close (0.05 < p ≤ 0.1)

In this analysis, carboplatin dose was a marginally significant factor (odds ratio, 2.06; 95% confidence interval, 0.99–4.29; p = 0.053).

also in 26,082 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.